Updated:
Ikena Oncology
ImageneBio, the public biotech formerly known as Ikena Oncology, develops an extended half-life anti-OX40 monoclonal antibody for autoimmune disease.
Ikena Oncology
Ikena Oncology reemerged as ImageneBio through a 2025 reverse merger with Inmagene Biopharmaceuticals, routing its oncology pipeline through a separate spin-out. The surviving public entity is now a pure-play immunology platform with operations anchored in Princeton and Boston. Its sole disclosed clinical asset is IMG-007, an extended half-life anti-OX40 monoclonal antibody designed to inhibit OX40 receptor signaling for immunological, autoimmune, and inflammatory diseases. The company organizes around a single-program strategy. IMG-007 is engineered to avoid T-cell depletion, a feature it claims may separate efficacy from safety in indications where earlier-generation OX40 or OX40L modulators disappointed. A virtual KOL event in May 2025 mapped the asset's potential in alopecia areata. No additional pipeline candidates or disclosed partner programs are cited in current corporate materials. ImageneBio last reported headcount and total capital deployment are undisclosed. A $30 million private placement closed in April 2026 provided bridge financing as the company stated it would continue IMG-007's clinical advancement. The firm listed itself for the 2026 Jefferies Global Healthcare Conference in May 2026. No philanthropic foundations or adjacent investment vehicles are noted. ImageneBio trades as a public micro-cap biotech — a structure that makes it an operating company rather than an investment allocation — following a reverse merger that left it focused on a single asset. Its governance and management disclosures remain thin: no named CEO, CIO, or board chair is surfaced in current investor-facing web content.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Princeton
Corporate office
Princeton, Boston, United States
Frequently asked questions
How does Ikena Oncology's 2025 reverse merger reshape the entity?
The 2025 transaction separated Ikena's legacy oncology programs into a privately held spin-out and merged the remaining shell with Inmagene Biopharmaceuticals. The surviving Nasdaq company was renamed ImageneBio and now focuses exclusively on immunology via the anti-OX40 antibody IMG-007. This architecture means the entity allocators previously tracked as an oncology play is no longer deploying capital toward cancer therapeutics.
What is IMG-007, and why does the firm consider it differentiated?
IMG-007 is an investigational anti-OX40 monoclonal antibody with an extended half-life. ImageneBio states it inhibits OX40 receptor signaling without depleting T cells — a design claim intended to improve the safety and dosing convenience profile relative to prior OX40-targeting attempts. The company has not published head-to-head clinical data against other OX40 or OX40L agents.
What indications is ImageneBio pursuing?
ImageneBio describes a pipeline targeting immunological, autoimmune, and inflammatory diseases. A May 2025 KOL event outlined potential application in alopecia areata. No registration-pathway indication has been formally declared in SEC filings cited through mid-2026.
What is ImageneBio's known deployment posture?
ImageneBio is not a fund or an investment vehicle — it is a publicly traded clinical-stage operating company. All internal resources support IMG-007's clinical advancement. A $30 million private placement in April 2026 provided near-term operating runway.
Who makes investment and strategic decisions at ImageneBio?
ImageneBio has not publicly identified its CEO, CIO, or board chair in currently available website disclosures. The management team and board composition are not surfaced in the firm's primary investor-facing materials, which is atypical for a Nasdaq-listed biotech and may reflect post-merger transition.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: